Morgan Stanley reiterated its Overweight rating for Eli Lilly and Company. The investment bank maintained a price target of $1,313 per share.
Prescriptions for Mounjaro and Zepbound showed significant growth for the week ending February 27, 2026. Eli Lilly’s total GLP-1 franchise captured approximately 60% of the weekly new prescription market share.
These trends reinforce the company's dominant position in the diabetes and obesity markets. The analyst outlook reflects high demand for the company's leading treatments and successful commercial execution.